DelveInsight's "Marginal Zone Lymphoma Market Insights, Epidemiology, and Market Forecast 2030" reports deliver an in-depth understanding of the Marginal Zone Lymphoma Market, historical and forecasted epidemiology, the pipeline insight as well as the Marginal Zone Lymphoma market size and shares analysis in the seven major markets (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
The Marginal Zone Lymphoma market report also covers emerging drugs, current treatment practices, Marginal Zone Lymphoma market shares of the individual therapies, current and forecasted Marginal Zone Lymphoma Market Size segmented by seven major markets.
The report provides a detailed current Marginal Zone Lymphoma treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the market.
The total incident population of Non-Hodgkin lymphoma (NHL) in the 7MM was estimated to be 166,967 in 2017. Out of these the total incident population of Marginal Zone Lymphoma in the 7MM in 2017 was observed to be 21,284. Based on the stages of the disease, Marginal Zone Lymphoma is divided into three stages. The epidemiological model of DelveInsight estimates a higher proportion of MZL cases was found in stage III as compared to other stages in the United States. In 2017, stage I, stage II, and stage III MZL incident cases were 1,416, 465 and 5,307 respectively, in the US. Among the EU5 countries, the UK had the highest incident population of Marginal Zone Lymphoma with 3,142 cases, followed by France which had an incident population of 1,748 in 2017
Marginal Zone Lymphoma Market Trends Analysis
Marginal Zone Lymphoma market size in the 7MM was found to be USD 427.16 Million in 2017. Marginal Zone Lymphoma market size is expected to increase during the forecast period owing to the increasing incident population of MZL patients in the 7MM and the launch of upcoming therapies during the forecast period.
The Marginal Zone Lymphoma market analysis section of the report helps to build a detailed comprehension of the historical, current, and forecasted Marginal Zone Lymphoma market trends and growth by analysing the impact of current therapies on the market, unmet needs, drivers, and barriers and demand for better technology.
The report gives complete detail of Marginal Zone Lymphoma market size and shares of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Marginal Zone Lymphoma Epidemiology Forecast
The Marginal Zone Lymphoma epidemiology section covers insights about historical and current Marginal Zone Lymphoma patient pool and forecasted trends for every seven major countries (i.e., the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
It helps to recognise the causes of current and forecasted Marginal Zone Lymphoma Epidemiology trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends, along with assumptions undertaken.
Several pharmaceutical key players have taken the initiative to meet the unmet needs of the present situation of the Marginal Zone Lymphoma market. Some of the key players are in the late and mid clinical development stages with their leading drug candidates. The launch of emerging products during the forecast period will fuel the Marginal Zone Lymphoma market growth.
Marginal Zone Lymphoma Companies operating the market include:
AbbVie
ArQule
AstraZeneca
Bayer
BeiGene
Bristol-Myers Squibb
Celgene Corporation
Cellectar Biosciences
Eli Lilly
Gilead Sciences
InnoCare Pharma
Innovent Biologics
Janssen Biotech
Loxo Oncology
MEI Pharma
Merck
NantKwest/ImmunityBio
Nordic Nanovector
Roche Pharma
TG Therapeutics
TriSalus Life Sciences
Verastem
Secura Bio
And many others
Marginal Zone Lymphoma Therapies covered in the report include Revlimid (lenalidomide) in combination with rituximab, Imbruvica (ibrutinib), Umbralisib (TGR-1202), Aliqopa (Copanlisib), Ublituximab, Obinutuzumab, Yescarta (axicabtagene ciloleucel), Keytruda (Pembrolizumab), CLR 131, Parsaclisib, Nivolumab (Oppdivo), Calquence (acalabrutinib), Betalutin (177Lu-satetraxetan-lilotomab), Navitoclax (ABT-263), Orelabrutinib (ICP-022), M7583, ARQ 531, Duvelisib, Zanubrutinib, Zandelisib, ALT-803, LOXO-305, SD-101, and many more.
For more details, visit: Marginal Zone Lymphoma Market Trends